AMENDMENT

Please amend the following claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

In the claims:

1. (Currently Amended) An ~~I~~isoxazolopyridone ~~derivatives~~ compound of a formula (I-a), or a pharmaceutically-acceptable salt thereof:



[I-a]

wherein R^{1a} represents an optionally-substituted heteroaryl ~~or phenyl~~ group, R^{2a} represents an optionally-substituted phenyl or heteroaryl group, and R^{3a} represents a methyl group, wherein the heteroaryl group is a 4- to 7-membered monocyclic group having from 1 to 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, or a condensed heteroaryl group of the monocyclic group that is condensed with a benzene or pyridine ring, and wherein the heteroaryl, phenyl, or condensed heteroaryl groups are optionally substituted with substituents comprising a lower alkyl group, a nitro group, a halogen atom, an amino group, a cyano group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a carbamoyl group, a lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a di-lower alkylamino group, and a lower alkylamino group ~~provided that, (1) when R^{1a} is an unsubstituted phenyl group, then R^{2a} must not be a para-substituted phenyl group of which the substituent is any of a methoxy group, a chloro group, a methyl group, a trifluoromethyl group, a fluoro group, a bromomethyl group or a dimethylaminomethyl group, and R^{2a} must not be an unsubstituted heteroaryl group, and (2) when R^{1a} is a 4-tolyl group or a 4-fluorophenyl group, then R^{2a} must not be an unsubstituted phenyl group, a 4-methoxyphenyl group or a 4-fluorophenyl group, or their pharmaceutically-acceptable salts~~.

2. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein R^{1a} is an optionally-substituted heteroaryl group selected from the group consisting of a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, an isothiazolyl group, an isoxazolyl group, a pyridyl group, a pyrimidinyl group, a quinolyl group, an isoquinolyl group, a quinazolyl group, a quinolidinyl group, a quinoxalinyl group, a cinnolinyl group, a benzimidazolyl group, an imidazopyridyl group, a benzofuranyl group, a naphthyridinyl group, a 1,2-benzisoxazolyl group, a benzoxazolyl group, a benzothiazolyl group, an oxazolopyridyl group, an isothiazolopyridyl group, and a benzothienyl group.

3. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein R^{1a} is an optionally-substituted pyridyl group.

4. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein R^{1a} is a 4-pyridyl group, and R^{2a} is a methoxy-substituted phenyl or pyridyl group.

5. (Cancelled)

6. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein ~~R^{1a} is a methoxy-substituted phenyl group, and~~ R^{2a} is an unsubstituted phenyl group.

7. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein R^{1a} is a 4-pyridyl group, and R^{2a} is a 3-methoxyphenyl or 4-methoxyphenyl group.

8. (Currently Amended) The ~~I~~isoxazolopyridone ~~derivatives~~ compound or ~~their~~ a pharmaceutically-acceptable ~~salts~~ salt thereof as claimed in claim 1, wherein ~~R^{1a} is an unsubstituted phenyl group, and~~ R^{2a} is a 5-methoxy-3-pyridyl, 3-methoxy-4-pyridyl, 5-dimethylamino-3-pyridyl, 3,4-methylenedioxyphenyl or 5-methoxy-2-pyridyl group.

9. (Withdrawn) A medicine for anxiety disorders, psychosomatic disorders, obsessive-compulsive neurosis, bipolar disorders, melancholia, eating disorders, schizophrenia, multi-infarct dementia, Alzheimer disease, epilepsy, Parkinson disease, Huntington's chorea, pain or retrograde neurosis, which comprises, as the active ingredient thereof, the novel isoxazolopyridone derivative of claims 1 to 8.

10. (New) The compound according to claim 1, wherein the compound represented by formulat (I-a) is: 5-methyl-6-(4-methoxyphenyl)-3-pyridin-4-yl-isoxazolo[4,5-c]pyridin-4(5H)-one, 5-methyl-3-pyridin-4-yl-6-phenylisoxazolo[4,5-c]pyridin-4(5H)-one, 5-methyl-3-pyridin-2-yl-6-phenylisoxazolo[4,5-c]pyridin-4(5H)-one, 5-methyl-3-pyridin-3-yl-6-phenylisoxazolo[4,5-c]pyridin-4(5H)-one, 5-methyl-6-(3-methoxyphenyl)-3-pyridin-4-yl-isoxazolo[4,5-c]pyridin-4(5H)-one, 5-methyl-6-pyridin-3-yl-3-pyridin-4-yl-isoxazolo[4,5-c]pyridin-4(5H)-one, or 5-methyl-6-pyridin-2-yl-3-pyridin-4-yl-isoxazolo[4,5-c]pyridin-4(5H)-one.